Market Overview

Integra LifeSciences Receives FDA Clearance for Expanded Indication for Spinal Device

Related IART
Integra LifeSciences Announces Changes Within Its Orthopedics And Tissue Technologies Business
Integra LifeSciences Announces Renewal And Extension Of Credit Facility; Increased From $600M to $900M

Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that the Food and Drug Administration (FDA) has approved an expanded indication for use of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures. The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate™. The Integra® Vu aPOD™ Prime IBD will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in Chicago, Illinois.

Posted-In: News FDA


Related Articles (IART)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters